Lista de obras - Aleix Prat - Dominio Público Uruguay

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

scientific article published on 05 February 2019

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells

artículo científico publicado en 2013

A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

scientific article published on 22 September 2020

A rare case of malignant solitary fibrous tumor of the spinal cord

artículo científico publicado en 2008

Acute lung injury associated with docetaxel and bevacizumab.

artículo científico publicado en 2007

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women

artículo científico publicado en 2014

Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.

artículo científico publicado en 2013

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.

artículo científico publicado en 2011

Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation

artículo científico publicado en 2014

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

scientific article published on 27 October 2013

Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.

artículo científico publicado en 2014

Clinical implementation of the intrinsic subtypes of breast cancer

scientific article published on 01 August 2010

Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib

artículo científico publicado en 2009

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

artículo científico publicado en 2012

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

artículo científico publicado en 2011

Defining breast cancer intrinsic subtypes by quantitative receptor expression

artículo científico publicado en 2015

Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.

artículo científico publicado en 2014

Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.

artículo científico publicado en 2013

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

scientific article published on 14 July 2020

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

artículo científico publicado en 2014

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

artículo científico publicado en 2013

Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.

artículo científico publicado en 2013

Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features

artículo científico publicado en 2011

Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast

artículo científico publicado en 2015

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

artículo científico publicado en 2014

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

artículo científico publicado en 2013

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.

artículo científico publicado en 2011

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes

artículo científico publicado en 2021

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

artículo científico publicado en 2020

Hepatic pneumatosis as a complication of an abdominal desmoid tumor

scientific article published on 01 March 2007

How many etiological subtypes of breast cancer: two, three, four, or more?

artículo científico publicado en 2014

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

artículo científico publicado en 2021

Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

artículo científico publicado en 2012

Mammary development meets cancer genomics

artículo científico publicado en 2009

MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.

artículo científico publicado en 2012

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

artículo científico publicado en 2013

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

artículo científico publicado en 2014

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

artículo científico publicado en 2014

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer

artículo científico publicado en 2007

New approaches in angiogenic targeting for colorectal cancer.

artículo científico publicado en 2007

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

artículo científico publicado en 2012

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

artículo científico publicado en 2013

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

scientific article published on 22 August 2012

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

artículo científico publicado en 2015

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

scientific article published on 16 September 2020

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

artículo científico publicado en 2020

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases ⬇️

artículo científico publicado el 1 de enero de 2011

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.

artículo científico publicado en 2014

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

artículo científico publicado en 2013

Practical implications of gene-expression-based assays for breast oncologists.

artículo científico publicado en 2011

Predicting drug responsiveness in human cancers using genetically engineered mice.

artículo científico publicado en 2013

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

artículo científico publicado en 2014

Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

artículo científico publicado en 2020

Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer

scientific article published on 01 April 2008

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer

artículo científico publicado en 2012

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

artículo científico publicado en 2015

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

artículo científico publicado en 2013

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

article

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

artículo científico publicado en 2015

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

artículo científico publicado en 2008

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer

scientific article published on 07 July 2020

SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling

artículo científico publicado en 2013

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

artículo científico publicado en 2019

Standardized versus research-based PAM50 intrinsic subtyping of breast cancer

scientific article published on 21 August 2019

Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy

artículo científico publicado en 2008

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.

artículo científico publicado en 2014

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

artículo científico publicado en 2012

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

artículo científico publicado en 2020

The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment

artículo científico publicado en 2014

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

artículo científico publicado en 2021

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

artículo científico publicado en 2012

Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients

scientific article published on 30 April 2020

Lista de obras de Aleix Prat

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells

A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

A rare case of malignant solitary fibrous tumor of the spinal cord

Acute lung injury associated with docetaxel and bevacizumab.

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women

Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.

Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.

Clinical implementation of the intrinsic subtypes of breast cancer

Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

Defining breast cancer intrinsic subtypes by quantitative receptor expression

Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.

Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.

Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features

Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Hepatic pneumatosis as a complication of an abdominal desmoid tumor

How many etiological subtypes of breast cancer: two, three, four, or more?

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

Mammary development meets cancer genomics

MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer

New approaches in angiogenic targeting for colorectal cancer.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases ⬇️

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

Practical implications of gene-expression-based assays for breast oncologists.

Predicting drug responsiveness in human cancers using genetically engineered mice.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer

SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Standardized versus research-based PAM50 intrinsic subtyping of breast cancer

Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients